Vaccine/immunisation Infections and Infestations Vaccination
Conditions
Interventions
Intervention: 1 dose of Rouvax® vaccine administered to the skin of the shoulder after stripping (abrading) the skin
Control: 1 dose of Rouvax® administered by injection
Sponsors
World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy adults between 18 and 22 years of age of haplotype HLA-A201 who have previously been immunised against measles and for whom the anti-measles antibodies are low 2. Female participants must be under contraception
Exclusion criteria
Exclusion criteria: 1. Previous infection with measles 2. Contra-indications to the use of Rouvax® vaccine 3. Hypersensitivity to egg proteins 4. Human Immunodeficiency Virus (HIV) seropositive 5. Treatment with corticosteroids or immunosuppressors in 15 days prior to enrolment 6. Exposure of back-skin to sun in 15 days prior to enrolment 7. Dermatological pathology on back 8. Acute and evolutive disease 9. Blood donation in three months prior to enrolment 10. In a period of exclusion following previous clinical trials 11. Having received 3800 or more Euros in preceeding 12 months from participation in clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
France
Outcome results
None listed